247 related articles for article (PubMed ID: 17495026)
1. The tumor suppressor CYLD regulates entry into mitosis.
Stegmeier F; Sowa ME; Nalepa G; Gygi SP; Harper JW; Elledge SJ
Proc Natl Acad Sci U S A; 2007 May; 104(21):8869-74. PubMed ID: 17495026
[TBL] [Abstract][Full Text] [Related]
2. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members.
Trompouki E; Hatzivassiliou E; Tsichritzis T; Farmer H; Ashworth A; Mosialos G
Nature; 2003 Aug; 424(6950):793-6. PubMed ID: 12917689
[TBL] [Abstract][Full Text] [Related]
3. Subquinocin, a small molecule inhibitor of CYLD and USP-family deubiquitinating enzymes, promotes NF-κB signaling.
Yamanaka S; Sato Y; Oikawa D; Goto E; Fukai S; Tokunaga F; Takahashi H; Sawasaki T
Biochem Biophys Res Commun; 2020 Mar; 524(1):1-7. PubMed ID: 31898971
[TBL] [Abstract][Full Text] [Related]
4. Negative regulation of JNK signaling by the tumor suppressor CYLD.
Reiley W; Zhang M; Sun SC
J Biol Chem; 2004 Dec; 279(53):55161-7. PubMed ID: 15496400
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells.
Urbanik T; Köhler BC; Boger RJ; Wörns MA; Heeger S; Otto G; Hövelmeyer N; Galle PR; Schuchmann M; Waisman A; Schulze-Bergkamen H
Int J Oncol; 2011 Jan; 38(1):121-31. PubMed ID: 21109933
[TBL] [Abstract][Full Text] [Related]
6. CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes.
Sun SC
Cell Death Differ; 2010 Jan; 17(1):25-34. PubMed ID: 19373246
[TBL] [Abstract][Full Text] [Related]
7. Update of cylindromatosis gene (CYLD) mutations in Brooke-Spiegler syndrome: novel insights into the role of deubiquitination in cell signaling.
Blake PW; Toro JR
Hum Mutat; 2009 Jul; 30(7):1025-36. PubMed ID: 19462465
[TBL] [Abstract][Full Text] [Related]
8. Expression of CYLD, NF-kappaB and NF-kappaB-related factors in salivary gland tumors.
Fukuda M; Fukuda F; Horiuchi Y; Oku Y; Suzuki S; Kusama K; Sakashita H
In Vivo; 2006; 20(4):467-72. PubMed ID: 16900776
[TBL] [Abstract][Full Text] [Related]
9. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination.
Kovalenko A; Chable-Bessia C; Cantarella G; Israël A; Wallach D; Courtois G
Nature; 2003 Aug; 424(6950):801-5. PubMed ID: 12917691
[TBL] [Abstract][Full Text] [Related]
10. CYLD suppression enhances the pro-inflammatory effects and hyperproliferation of rheumatoid arthritis fibroblast-like synoviocytes by enhancing NF-κB activation.
Zhang LM; Zhou JJ; Luo CL
Arthritis Res Ther; 2018 Oct; 20(1):219. PubMed ID: 30285829
[TBL] [Abstract][Full Text] [Related]
11. The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module.
Komander D; Lord CJ; Scheel H; Swift S; Hofmann K; Ashworth A; Barford D
Mol Cell; 2008 Feb; 29(4):451-64. PubMed ID: 18313383
[TBL] [Abstract][Full Text] [Related]
12. Tumor suppressor CYLD: negative regulation of NF-kappaB signaling and more.
Courtois G
Cell Mol Life Sci; 2008 Apr; 65(7-8):1123-32. PubMed ID: 18193168
[TBL] [Abstract][Full Text] [Related]
13. Loss of CYLD might be associated with development of salivary gland tumors.
Fukuda M; Hiroi M; Suzuki S; Ohmori Y; Sakashita H
Oncol Rep; 2008 Jun; 19(6):1421-7. PubMed ID: 18497946
[TBL] [Abstract][Full Text] [Related]
14. Expression of CYLD and NF-kappaB in human cholesteatoma epithelium.
Byun JY; Yune TY; Lee JY; Yeo SG; Park MS
Mediators Inflamm; 2010; 2010():796315. PubMed ID: 20414373
[TBL] [Abstract][Full Text] [Related]
15. SPATA2 promotes CYLD activity and regulates TNF-induced NF-κB signaling and cell death.
Schlicher L; Wissler M; Preiss F; Brauns-Schubert P; Jakob C; Dumit V; Borner C; Dengjel J; Maurer U
EMBO Rep; 2016 Oct; 17(10):1485-1497. PubMed ID: 27458237
[TBL] [Abstract][Full Text] [Related]
16. The E3 ubiquitin ligase MIB2 enhances inflammation by degrading the deubiquitinating enzyme CYLD.
Uematsu A; Kido K; Takahashi H; Takahashi C; Yanagihara Y; Saeki N; Yoshida S; Maekawa M; Honda M; Kai T; Shimizu K; Higashiyama S; Imai Y; Tokunaga F; Sawasaki T
J Biol Chem; 2019 Sep; 294(38):14135-14148. PubMed ID: 31366726
[TBL] [Abstract][Full Text] [Related]
17. NF-kappaB is essential for induction of CYLD, the negative regulator of NF-kappaB: evidence for a novel inducible autoregulatory feedback pathway.
Jono H; Lim JH; Chen LF; Xu H; Trompouki E; Pan ZK; Mosialos G; Li JD
J Biol Chem; 2004 Aug; 279(35):36171-4. PubMed ID: 15226292
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of CYLD downregulation in breast cancer.
Hayashi M; Jono H; Shinriki S; Nakamura T; Guo J; Sueta A; Tomiguchi M; Fujiwara S; Yamamoto-Ibusuki M; Murakami K; Yamashita S; Yamamoto Y; Li JD; Iwase H; Ando Y
Breast Cancer Res Treat; 2014 Feb; 143(3):447-57. PubMed ID: 24398777
[TBL] [Abstract][Full Text] [Related]
19. Adenoviral vector expressing CYLD augments antitumor activity of TRAIL by suppression of NF-kappaB survival signaling in hepatocellular carcinoma.
Chu L; Gu J; He Z; Xiao T; Liu X
Cancer Biol Ther; 2006 Jun; 5(6):615-22. PubMed ID: 16627981
[TBL] [Abstract][Full Text] [Related]
20. [Research progress of deubiquitinating enzyme CYLD to regulate liver-related diseases].
Yang X; An DJ; Gao CC; Qin HY
Zhonghua Gan Zang Bing Za Zhi; 2019 Jun; 27(6):477-480. PubMed ID: 31357769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
